6th Oct 2005 11:30
6 October 2005Shire Pharmaceuticals Group plc (the "Company")The trustee of the Shire Pharmaceuticals Group plc Employee Benefit Trust (the"Trust") notified the Company on 4 October 2005 that, on that day, it exercisedits discretion and released a total of 293 ordinary shares in the Company fornil consideration, being the release of shares to a beneficiary of the Trust onsatisfaction of an award under the Shire Pharmaceuticals 2003 Deferred BonusPlan. None of the shares released were in respect of an award made to adirector of the Company.Following this transaction, the trustee holds a total of 50,993 ordinary sharesin the Company. The executive directors of the Company are amongst thepotential beneficiaries under the Trust and are therefore regarded forCompanies Act purposes as being interested in the shares held in them pursuantto DR 3.1.4R(1)(6).Tatjana MayCompany SecretaryFor further information please contact:Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Brian Piper (North America) +1 484 595 8252 Notes to editorsShire Pharmaceuticals Group plcShire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceuticalcompany with a strategic focus on meeting the needs of the specialist physicianand currently focuses on developing and marketing products in the areas ofcentral nervous system (CNS), gastrointestinal (GI), renal diseases and humangenetic therapies. Shire has operations in the world's key pharmaceuticalmarkets (US, Canada, UK, France, Italy, Spain and Germany) as well as aspecialist drug delivery unit in the US.For further information on Shire, please visit the Company's website: www.shire.com. Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release Registered in England 2883758 Registered Office as aboveENDShire Pharmaceuticals Group PLCRelated Shares:
Shire